MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
home > drug information > Lamisil

Lamisil (terbinafine hydrochloride) Solution, 1%


Company: Novartis
Approval Status: Approved March 2000
Treatment for: For the treatment of interdigital-type pedis (athlete's foot), tinea cruris (jock itch) and tinea corporis (ringworm)
Areas: Dermatology/Plastic Surgery; Immunology/Infectious Diseases
Possible similar drugs: Lamisil; Lamisil Solution, 1%

| General Information | Clinical Results | Side Effects | Mechanism of Action | Additional Information |


General Information

Other Useful Resources

Lamisil Solution has been approved for the treatment of interdigital-type pedis (athlete's foot), tinea cruris (jock itch) and tinea corporis (ringworm) due to Trichophyton rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum. This product contains the same prescription-strength medication as in the Lamilsi Cream. Both products have been approved for over-the-counter sales for the above indications. Lamisil Solution is also available as prescription-only for the indication of tinea versicolor.

Lamisil is a one week treatment, whereas most or all other over-the-counter (OTC) treatments for athlete's foot and other fungal infections are four week treatments. The product should be applied once daily for the treatment of tinea corporis and tinea cruris, and twice daily for the treatment of tinea pedis and tinea versicolor.

The indications:

  • Tinea cruris (jock itch) is a fungal infection of the groin and gluteal cleft
  • Tinea corporis (ringworm) is an infection of the body surface with mold-like fungi called dermatophytes. It often affects children, but can occur in people of all ages.
  • Tinea pedis (Athlete's foot) is a fungal infection of the foot. It affects 1 out of 10 Americans each year and 75% of Americans over their lifetime. A majority of sufferers are males, ages 25-54. Athlete's foot can manifest itself in a variety of ways, ranging from moist, easily rubbed-off skin, to red flaky skin. Symptoms often include itching, blisters and cracking.
  • Pityriasis (tinea) versicolor is a superficial infection caused by a commensal yeast. It is characterized by lesions, scaling and discoloration of the skin. Tinea versicolor affects mostly young adults, but can affect a person in any age group.

All of these fungal conditions are contagious. Good hygiene, keeping skin dry, and protecting minor skin injuries can all help prevent the spread of these fungal infections.

Other products with the Lamisil name:

  • Lamisil Tablets prescription oral medication for the treatment of fungal nail infection (onychomycosis)
  • Lamisil Cream over-the-counter cream medication for the treatment of athlete's foot, jock itch, and ringworm

< back to top

Clinical Results

In clinical studies, the Lamisil Solution treatment was investigated versus placebo, for each of the indications. Results showed that at both the end of the one-week treatment period and at the end of the study (8 weeks), patients treated with Lamisil Solution achieved much better effective treatment and complete cure results than did the patients treated with the placebo.



< back to top

Side Effects

Adverse reactions reported by Lamisil Solution-treated patients during clinical studies:

  • Application site reactions, such as burning or irritation (occurred in 1.3% of patients)
  • Itching (occurred in 1.1% of patients)
  • Skin exfoliation (occurred in 1.0% or patients)
  • Erythematous rash (occurred in 0.9% of patients)

0.2% or the 898 patients participating in clinical trials discontinued therapy due to adverse reactions.

Lamisil Solution is not for ophthalmic, oral, or intravaginal use.



< back to top

Mechanism of Action

Terbinafine hydrochloride is a synthetic allylamine derivative. Terbinafine hydrochloride is hypothesized to act by inhibiting the epoxidation of squalene, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. The allylamine derivatives, like the benzylamines, act at an earlier step in the ergosterol biosynthesis pathway than the azole class of antifungal drugs. Depending on the concentration of the drug and the fungal species tested in vitro, terbinafine hydrochloride may be fungicidal. However, the clinical significance of in vitro data is unknown. (From FDA Label)



< back to top

Additional Information

Visit the Novartis Pharmaceuticals Corporation web site to learn more about Lamisil Solution and about other products, research, and services provided by the company that developed this drug.

To search the internet for dermatology-related topics, visit www.dermguide.com, an internet search engine devoted to dermatological issues.

For more information about current events in dermatology, case studies in dermatology, interactive emailing with experts in dermatology, etc., visit www.skindex.com.



< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.




free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.